Preventive Approach Using Venlafaxine
Peripheral Neuropathy Due to Chemotherapy
About this trial
This is an interventional treatment trial for Peripheral Neuropathy Due to Chemotherapy focused on measuring Peripheral neuropathy, Taxanes, oxaliplatin, Chemotherapy, Venlafaxine
Eligibility Criteria
Inclusion Criteria: Patients >24 years of age, men or women to lower risk of suicidal tendency. Patients with histologically proven cancer Patients receiving oxaliplatin or taxanes-based regimen WHO performance status of 0-2 serum AST or ALT no higher than two times the upper limit of normal serum creatinine level less than 2 mg/dL platelet count of at least 100,000/mm3 absolute neutrophil count of at least to 1.0 G/L Female patients, those with a negative urine pregnancy test. Exclusion Criteria: Patients with brain or leptomeningeal metastasis. Patients with previous platinum-based chemotherapy Patients with history of alcoholic intoxication, diabetes, preexisting neuropathy or unstable psychological conditions. Patients with history of calcium/magnesium concomitant infusions, use of antiepileptics, antidepressants or lithium.
Sites / Locations
- Mit Ghamr Oncology CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Venlafaxine Arm
Gabapentin Arm
Patients receiving Taxanes (Docetaxel or Paclitaxel) or Oxaliplatin containing regimens.
Patients receiving Taxanes (Docetaxel or Paclitaxel) or Oxaliplatin containing regimens.